caa a22 4500 606158715 CHVBK 20210128100621.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10557-015-6616-3 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6616-3 Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy [Elektronische Daten] [Monica Verdoia, Patrizia Pergolini, Roberta Rolla, Matteo Nardin, Lucia Barbieri, Alon Schaffer, Giorgio Bellomo, Paolo Marino, Harry Suryapranata, Giuseppe De Luca] Background: Low response to antiplatelet agents has been associated to an increased risk of thrombotic complications and recurrent ischemic events. Platelet size has been proposed as a potential marker of platelet reactivity. Therefore, the aim of the present study was to evaluate the impact of platelet Larger Cell Ratio (p-LCR) on platelet aggregation and the prevalence of residual high-on treatment platelet reactivity (HRPR) in patients receiving dual antiplatelet therapy (DAPT) after a recent acute coronary syndrome or coronary revascularization. Methods: Patients treated with DAPT (ASA and clopidogrel or ticagrelor) were scheduled for platelet function assessment at 30-90days post-discharge. HRPR was considered for ASPI test >862AU*min (for ASA) or ADP test values ≥417AU*min (for ADP-antagonists) using impedance aggregometry. Results: Our population consisted of 530 patients receiving DAPT, who were divided in tertiles according to values of p-LCR (< 27.6; 27.6-34.7; ≥34.7l). p-LCR was related with use of beta-blockers (p=0.02) and statins (p=0.002), and inversely with acute presentation (p=0.05). Higher platelet count (p<0.001) and haemoglobin levels (p=0.001) were observed in higher p-LCR tertiles. The prevalence of HRPR for ASA was low and not significantly different across tertiles of p-LCR (1.1 vs 1.1 vs 1.7%, p=0.66; adjusted OR[95%CI]=1.68[0.66-4.29], p=0.27). Moreover, p-LCR did not influence the occurrence of HRPR for ADP-antagonists (24.4% vs 20.9% vs 25.6%%, p=0.80, adjusted OR[95%CI]=0.88[0.67-1.17], p=0.38) and similar results were obtained when considering separately patients receiving clopidogrel (adjusted OR[95%CI]=1.21[0.86-1.69], p=0.29) or ticagrelor (adjusted OR[95%CI]=1.17[0.69-2], p=0.56). Conclusion: In patients receiving DAPT for coronary artery disease, p-LCR does not impact platelet reactivity. Larger platelets did not influence the prevalence of high-on treatment platelet reactivity with the antiplatelet agents ASA, clopidogrel or ticagrelor. Springer Science+Business Media New York, 2015 Platelet larger cell ratio nationallicence Platelet aggregation nationallicence Dual antiplatelet therapy nationallicence Clopidogrel nationallicence Ticagrelor nationallicence Coronary artery disease nationallicence Verdoia Monica Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut Pergolini Patrizia Clinical Chemistry, Ospedale "Maggiore della Carità”, Eastern Piedmont University, Novara, Italy aut Rolla Roberta Clinical Chemistry, Ospedale "Maggiore della Carità”, Eastern Piedmont University, Novara, Italy aut Nardin Matteo Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut Barbieri Lucia Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut Schaffer Alon Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut Bellomo Giorgio Clinical Chemistry, Ospedale "Maggiore della Carità”, Eastern Piedmont University, Novara, Italy aut Marino Paolo Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut Suryapranata Harry Cardiology, UMC St Radboud, Nijmegen, The Netherlands aut De Luca Giuseppe Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/5(2015-10-01), 443-450 0920-3206 29:5<443 2015 29 10557 https://doi.org/10.1007/s10557-015-6616-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6616-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Verdoia Monica Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut NATIONALLICENCE 700 1- Pergolini Patrizia Clinical Chemistry, Ospedale "Maggiore della Carità”, Eastern Piedmont University, Novara, Italy aut NATIONALLICENCE 700 1- Rolla Roberta Clinical Chemistry, Ospedale "Maggiore della Carità”, Eastern Piedmont University, Novara, Italy aut NATIONALLICENCE 700 1- Nardin Matteo Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut NATIONALLICENCE 700 1- Barbieri Lucia Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut NATIONALLICENCE 700 1- Schaffer Alon Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut NATIONALLICENCE 700 1- Bellomo Giorgio Clinical Chemistry, Ospedale "Maggiore della Carità”, Eastern Piedmont University, Novara, Italy aut NATIONALLICENCE 700 1- Marino Paolo Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut NATIONALLICENCE 700 1- Suryapranata Harry Cardiology, UMC St Radboud, Nijmegen, The Netherlands aut NATIONALLICENCE 700 1- De Luca Giuseppe Department of Cardiology, Ospedale "Maggiore della Carità”, Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/5(2015-10-01), 443-450 0920-3206 29:5<443 2015 29 10557